MARKET

IMDX

IMDX

Insight Molecular Diagnostics Inc.
NASDAQ
6.33
+1.23
+24.12%
Opening 14:28 05/14 EDT
OPEN
4.920
PREV CLOSE
5.10
HIGH
6.75
LOW
4.910
VOLUME
789.21K
TURNOVER
--
52 WEEK HIGH
8.51
52 WEEK LOW
2.330
MARKET CAP
204.38M
P/E (TTM)
-3.8413
1D
5D
1M
3M
1Y
5Y
1D
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)
TipRanks · 6h ago
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
TipRanks · 8h ago
Insight Molecular Q1 2026 Earnings Call Transcript
Benzinga · 10h ago
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M
Seeking Alpha · 19h ago
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Reuters · 23h ago
*Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX
Dow Jones · 23h ago
*Insight Molecular Diagn 1Q Rev $32,000 >IMDX
Dow Jones · 23h ago
Insight Molecular Diagnostics Q1 FY26 net loss narrows to $4.29 million; revenue drops to $32,000
PUBT · 23h ago
More
About IMDX
Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Webull offers Insight Molecular Diagnostics Inc stock information, including NASDAQ: IMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMDX stock methods without spending real money on the virtual paper trading platform.